本帖最后由 老马 于 2012-1-13 21:20 编辑
9 ^6 d( J7 t0 t: o0 t* o4 }- l# Q; \4 J! S* \
爱必妥和阿瓦斯丁的比较# `8 i, y; }, z9 \
$ Z3 t6 S0 f6 f- i1 _http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
, f# y- p0 \5 Z" |) C: l
# t( T6 Y5 p7 x O' k+ t0 C3 _
' a1 t8 H; S/ v8 Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 N4 \& s! r) c$ s9 q( E: a# l
==================================================( l$ c( N! L0 ]' z+ o4 _2 Q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# W5 v. u; H4 X# n$ u6 x+ I0 [Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% e6 z: g* e1 t: ]- u4 `) \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: n* [( ?5 L+ R2 [, P
|
显身卡
